MarketCap
Facebook
X
Telegram
Varex Imaging Corporation EBITDA | VREX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Varex Imaging Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.6 M | 53.3 M | 96.6 M | 107 M | 94.6 M | -11.4 M | 84.9 M | 86.7 M | 111 M | 124 M | 140 M | 186 M | 179 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 186 M | -11.4 M | 96 M |
Quarterly EBITDA Varex Imaging Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -79.7 M | 25.8 M | 21.1 M | 21.1 M | - | -79.7 M | 23.1 M | 17.4 M | - | 11 M | 11.3 M | 9.3 M | - | 27.6 M | 19 M | 17.6 M | - | 26.7 M | 30.3 M | 18.8 M | - | 36.2 M | 20.1 M | 9.8 M | -3.5 M | -15.4 M | 5.8 M | - | 48.2 M | 18.7 M | 18.1 M | 20.2 M | 54.1 M | 17.8 M | 20.2 M | 18.5 M | 67.7 M | 24 M | 18.5 M | 21.7 M | 83.3 M | 32.8 M | 21.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 83.3 M | -79.7 M | 17.8 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
9.49 B | $ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | - | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
783 M | $ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
-33.1 M | $ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
9.42 B | $ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
78.8 M | $ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
-7.46 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
-66 M | - | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
-13.5 M | $ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
564 M | $ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
-40.9 M | $ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
-110 M | $ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
-20.4 M | - | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
1.37 B | $ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
-9.91 M | $ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
6.46 B | $ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
35.9 M | $ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
136 M | $ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
-188 M | - | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
51.6 M | $ 9.04 | 1.01 % | $ 352 M | USA |
 |
Acutus Medical
AFIB
|
240 K | - | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
-18.6 M | $ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
-47 M | - | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
12.5 M | $ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.19 B | $ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-77 M | $ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
207 M | $ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
-102 M | - | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
-34.1 M | - | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
-23.3 M | - | - | $ 726 K | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
-62.4 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-56.6 M | - | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
-76.3 M | - | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
169 M | - | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
-7.14 M | - | - | $ 4.23 B | USA |